Is systemic infliximab therapy effective for retinal cavernous hemangioma?

Abstract	A 10-month-old infant with the diagnosis of retinal cavernous hemangioma involving the macula presented with an outward deviation of the right eye that has been noticed by her parents. Examination revealed a clearing vitreous hemorrhage, and grape-like clusters filled with blood in the posterior pole. After 4 cycles of intravenous infliximab over the period of 3 months, no evident change was noted on the size of the cavernous hemangioma.
Authors	Sulaiman M Alsulaiman, Marwan A Abouammoh, Saad A Al-Dahmash, Ahmed M Abu El-Asrar
Journal	Saudi medical journal (Saudi Med J) Vol. 35 Issue 9 Pg. 1127-30 (Sep 2014) ISSN: 0379-5284 [Print] Saudi Arabia
PMID	25228188 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Infliximab
Topics	Antibodies, Monoclonal (administration & dosage, therapeutic use) Female Hemangioma, Cavernous (drug therapy) Humans Infant Infliximab Retinal Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!